A Prospective Phase I/II Dose Escalation Pilot Analysis of Ruboxistaurin (LY333531) for Safety in New York Heart Failure Classification III-IV Patients, As Well As For Efficacy in Acutely Augmenting Cardiac Function.
Phase of Trial: Phase I/II
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Ruboxistaurin (Primary)
- Indications Heart failure
- Focus Adverse reactions
- 12 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 12 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 28 Jul 2017 Status changed from not yet recruiting to recruiting.